Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday.
Paul Matteis has given his Buy rating due to a combination of factors surrounding GH Research’s promising developments. The announcement of positive results from phase 2a studies in postpartum depression (PPD) and bipolar II disorder (BPD/BDII) has demonstrated robust efficacy and significant remission rates, indicating a strong antidepressant signal. These findings enhance confidence in the efficacy profile of their lead compound, GH001, as it progresses towards more critical phase 2b trials in treatment-resistant depression (TRD), which are expected to report outcomes in the first quarter of 2025.
Furthermore, the safety profile of GH001 appears favorable, with no serious adverse events reported, which supports its potential as a therapeutic option. Regulatory progress is also noteworthy, as GH Research has completed necessary animal toxicology studies without concerning findings and plans to engage with the FDA to resolve an existing clinical hold. Collectively, these clinical, safety, and regulatory updates are encouraging and justify the optimistic outlook for GH Research’s stock.
Matteis covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, uniQure, and Denali Therapeutics. According to TipRanks, Matteis has an average return of 0.7% and a 38.95% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.
GH Research (GHRS) Company Description:
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
